{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:57:16Z","timestamp":1794272236710,"version":"4.9.0"},"reference-count":246,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Foundation of Korea, South Korea","award":["Project No: 2022R1F1A1075002"],"award-info":[{"award-number":["Project No: 2022R1F1A1075002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"DOI":"10.1186\/s13046-026-03720-8","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:44:33Z","timestamp":1777869873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance"],"prefix":"10.1186","volume":"45","author":[{"given":"Prashant","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Phuong","family":"Thuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israrul H.","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Mani","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinalini","family":"Kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa H.","family":"Elberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"3720_CR1","doi-asserted-by":"publisher","unstructured":"Ramos A, Sadeghi S, Tabatabaeian H. Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them. Int J Mol Sci. 2021;22(17). https:\/\/doi.org\/10.3390\/ijms22179451. From NLM.","DOI":"10.3390\/ijms22179451"},{"key":"3720_CR2","doi-asserted-by":"publisher","unstructured":"Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MF-R, Ahmed H, Rahman N, Nainu F, Wahyudin E, et al. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front Oncol. 2022;12.\u00a0https:\/\/doi.org\/10.3389\/fonc.2022.891652. Review.","DOI":"10.3389\/fonc.2022.891652"},{"issue":"2","key":"3720_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.20517\/cdr.2019.10","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141\u201360. https:\/\/doi.org\/10.20517\/cdr.2019.10. From NLM.","journal-title":"Cancer Drug Resist"},{"key":"3720_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-3-031-27156-4_12","volume":"185","author":"M Adil","year":"2023","unstructured":"Adil M, Kanwal S, Rasheed S, Iqbal M, Abbas G. Cancer Chemoresistance; Recent Challenges and Future Considerations. Cancer Treat Res. 2023;185:237\u201353. https:\/\/doi.org\/10.1007\/978-3-031-27156-4_12. From NLM.","journal-title":"Cancer Treat Res"},{"key":"3720_CR5","doi-asserted-by":"publisher","unstructured":"Salemme V, Centonze G, Avalle L, Natalini D, Piccolantonio A, Arina P, Morellato A, Ala U, Taverna D, Turco E, et al. The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity. Front Oncol. 2023;13.\u00a0https:\/\/doi.org\/10.3389\/fonc.2023.1170264. Review.","DOI":"10.3389\/fonc.2023.1170264"},{"key":"3720_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.bioactmat.2023.08.022","volume":"31","author":"P Sharma","year":"2024","unstructured":"Sharma P, Otto M. Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy. Bioact Mater. 2024;31:440\u201362. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.08.022. From NLM PubMed-not-MEDLINE.","journal-title":"Bioact Mater"},{"key":"3720_CR7","doi-asserted-by":"publisher","unstructured":"Liu Y, Liang J, Zhang Y, Guo Q. Drug resistance and tumor immune microenvironment: An overview of current understandings (Review). Int J Oncol. 2024;65(4). https:\/\/doi.org\/10.3892\/ijo.2024.5684. From NLM.","DOI":"10.3892\/ijo.2024.5684"},{"key":"3720_CR8","doi-asserted-by":"publisher","unstructured":"Bartosz W, Alicja D, Julita K, Dagmara B. Chemoresistance and the tumor microenvironment: the critical role of cell\u2013cell communication. Cell Commun Signal. 2024;22(1). https:\/\/doi.org\/10.1186\/s12964-024-01857-7.","DOI":"10.1186\/s12964-024-01857-7"},{"issue":"8","key":"3720_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.Cd-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash J, Shaked Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 2024;14(8):1375\u201388. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0002. From NLM.","journal-title":"Cancer Discov"},{"issue":"2","key":"3720_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.20517\/cdr.2018.11","volume":"2","author":"L Ponnusamy","year":"2019","unstructured":"Ponnusamy L, Mahalingaiah PKS, Chang YW, Singh KP. Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer. Cancer Drug Resist. 2019;2(2):297\u2013312. https:\/\/doi.org\/10.20517\/cdr.2018.11. From NLM.","journal-title":"Cancer Drug Resist"},{"issue":"11","key":"3720_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.trecan.2023.07.006","volume":"9","author":"M Kalli","year":"2023","unstructured":"Kalli M, Poskus MD, Stylianopoulos T, Zervantonakis IK. Beyond matrix stiffness: targeting force-induced cancer drug resistance. Trends Cancer. 2023;9(11):937\u201354. https:\/\/doi.org\/10.1016\/j.trecan.2023.07.006.","journal-title":"Trends Cancer"},{"issue":"1","key":"3720_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ygyno.2011.03.036","volume":"122","author":"RL Coleman","year":"2011","unstructured":"Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(1):111\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2011.03.036. From NLM.","journal-title":"Gynecol Oncol"},{"key":"3720_CR13","doi-asserted-by":"publisher","first-page":"106586","DOI":"10.1016\/j.ejps.2023.106586","volume":"191","author":"Q Fernandes","year":"2023","unstructured":"Fernandes Q, Therachiyil L, Khan AQ, Bedhiafi T, Korashy HM, Bhat AA, et al. Shrinking the battlefield in cancer therapy: nanotechnology against cancer stem cells. Eur J Pharm Sci. 2023;191:106586. https:\/\/doi.org\/10.1016\/j.ejps.2023.106586.","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"3720_CR14","first-page":"5155","volume":"11","author":"PJ Kaboli","year":"2021","unstructured":"Kaboli PJ, Imani S, Jomhori M, Ling KH. Chemoresistance in breast cancer: PI3K\/Akt pathway inhibitors vs the current chemotherapy. Am J Cancer Res. 2021;11(10):5155\u201383. From NLM.","journal-title":"Am J Cancer Res"},{"key":"3720_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.dnarep.2016.06.003","volume":"45","author":"M Majidinia","year":"2016","unstructured":"Majidinia M, Yousefi B. Long non-coding RNAs in cancer drug resistance development. DNA Repair. 2016;45:25\u201333. https:\/\/doi.org\/10.1016\/j.dnarep.2016.06.003.","journal-title":"DNA Repair"},{"issue":"1","key":"3720_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, Yang P, Chen C, Ding W, Tillement O, Bai H, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther. 2025;10(1):219. https:\/\/doi.org\/10.1038\/s41392-025-02266-z.","journal-title":"Signal Transduct Target Ther"},{"key":"3720_CR17","doi-asserted-by":"publisher","unstructured":"Amirmahani F, Kumar S, Muthukrishnan SD. Epigenetic mechanisms of plasticity and resistance in glioblastoma: therapeutic targets and implications. Front Epigenet Epigenomics. 2025;3.\u00a0https:\/\/doi.org\/10.3389\/freae.2025.1519449. Review.","DOI":"10.3389\/freae.2025.1519449"},{"issue":"15","key":"3720_CR18","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-25-0999","volume":"85","author":"EA Oliveira","year":"2025","unstructured":"Oliveira EA, Milite S, Fernandez-Mateos J, Cresswell GD, Yara-Romero E, Vlachogiannis G, et al. Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance through a One-to-Many Genotype-to-Phenotype Paradigm. Can Res. 2025;85(15):2921\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0999. Accessed 8\/24\/2025.","journal-title":"Can Res"},{"issue":"12","key":"3720_CR19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3390\/pharmaceutics16121549","volume":"16","author":"W Meng","year":"2024","unstructured":"Meng W, Huang L, Guo J, Xin Q, Liu J, Hu Y. Innovative nanomedicine delivery: targeting tumor microenvironment to defeat drug resistance. Pharmaceutics. 2024;16(12):1549.","journal-title":"Pharmaceutics"},{"issue":"16","key":"3720_CR20","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081. From NLM Medline.","journal-title":"Curr Biol"},{"issue":"7","key":"3720_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409\u201325. https:\/\/doi.org\/10.1038\/nrc3958. From NLM Medline.","journal-title":"Nat Rev Cancer"},{"key":"3720_CR22","doi-asserted-by":"publisher","first-page":"608406","DOI":"10.1155\/2012\/608406","volume":"2012","author":"V Chew","year":"2012","unstructured":"Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012;2012:608406. https:\/\/doi.org\/10.1155\/2012\/608406. From NLM PubMed-not-MEDLINE.","journal-title":"J Oncol"},{"issue":"9","key":"3720_CR23","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3390\/cells9092102","volume":"9","author":"E Bockamp","year":"2020","unstructured":"Bockamp E, Rosigkeit S, Siegl D, Schuppan D. Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology. Cells. 2020;9(9):2102.","journal-title":"Cells"},{"issue":"1","key":"3720_CR24","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1038\/s41467-019-11719-3","volume":"10","author":"A Galstyan","year":"2019","unstructured":"Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, et al. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun. 2019;10(1):3850. https:\/\/doi.org\/10.1038\/s41467-019-11719-3. From NLM Medline.","journal-title":"Nat Commun"},{"key":"3720_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2015.08.027","volume":"217","author":"L Miao","year":"2015","unstructured":"Miao L, Wang Y, Lin CM, Xiong Y, Chen N, Zhang L, et al. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J Control Release. 2015;217:27\u201341. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.027. From NLM Medline.","journal-title":"J Control Release"},{"issue":"1","key":"3720_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-017-0596-9","volume":"16","author":"TB Toh","year":"2017","unstructured":"Toh TB, Lim JJ, Chow EK-H. Epigenetics in cancer stem cells. Mol Cancer. 2017;16(1):29. https:\/\/doi.org\/10.1186\/s12943-017-0596-9.","journal-title":"Mol Cancer"},{"key":"3720_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejpb.2018.09.010","volume":"132","author":"MBC de Matos","year":"2018","unstructured":"de Matos MBC, Beztsinna N, Heyder C, Fens MHAM, Mastrobattista E, Schiffelers RM, et al. Thermosensitive liposomes for triggered release of cytotoxic proteins. Eur J Pharm Biopharm. 2018;132:211\u201321. https:\/\/doi.org\/10.1016\/j.ejpb.2018.09.010.","journal-title":"Eur J Pharm Biopharm"},{"key":"3720_CR28","doi-asserted-by":"publisher","first-page":"111430","DOI":"10.1016\/j.matdes.2022.111430","volume":"224","author":"Q Li","year":"2022","unstructured":"Li Q, Wu T, Fan X, Guo X, Jiang W, Fan K. Multifaceted nanozymes for synergistic antitumor therapy: a review. Mater Des. 2022;224:111430. https:\/\/doi.org\/10.1016\/j.matdes.2022.111430.","journal-title":"Mater Des"},{"issue":"45","key":"3720_CR29","doi-asserted-by":"publisher","first-page":"8266","DOI":"10.1002\/adfm.201603336","volume":"26","author":"X Wei","year":"2016","unstructured":"Wei X, Wang Y, Xiong X, Guo X, Zhang L, Zhang X, et al. Codelivery of a \u03c0\u2013\u03c0 stacked dual anticancer drug combination with nanocarriers for overcoming multidrug resistance and tumor metastasis. Adv Funct Mater. 2016;26(45):8266\u201380. https:\/\/doi.org\/10.1002\/adfm.201603336.","journal-title":"Adv Funct Mater"},{"issue":"22","key":"3720_CR30","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1158\/0008-5472.Can-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee N, Gupta R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 2021;81(22):5589\u201395. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-1606. From NLM.","journal-title":"Cancer Res"},{"key":"3720_CR31","doi-asserted-by":"publisher","unstructured":"Subhan MA, Filipczak N, Torchilin VP. Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers. Pharmaceuticals (Basel). 2023;16(7). https:\/\/doi.org\/10.3390\/ph16070970. From NLM.","DOI":"10.3390\/ph16070970"},{"key":"3720_CR32","doi-asserted-by":"publisher","unstructured":"Duan L, Ouyang K, Xu X, Xu L, Wen C, Zhou X, Qin Z, Xu Z, Sun W, Liang Y. Nanoparticle Delivery of CRISPR\/Cas9 for Genome Editing. Front Genet. 2021;12.\u00a0https:\/\/doi.org\/10.3389\/fgene.2021.673286. Review.","DOI":"10.3389\/fgene.2021.673286"},{"issue":"1","key":"3720_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s11658-022-00348-2","volume":"27","author":"M Vaghari-Tabari","year":"2022","unstructured":"Vaghari-Tabari M, Hassanpour P, Sadeghsoltani F, Malakoti F, Alemi F, Qujeq D, et al. CRISPR\/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. Cell Mol Biol Lett. 2022;27(1):49. https:\/\/doi.org\/10.1186\/s11658-022-00348-2.","journal-title":"Cell Mol Biol Lett"},{"issue":"12","key":"3720_CR34","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/gt.2016.67","volume":"23","author":"SK Jones","year":"2016","unstructured":"Jones SK, Merkel OM. Tackling breast cancer chemoresistance with nano-formulated siRNA. Gene Ther. 2016;23(12):821\u20138. https:\/\/doi.org\/10.1038\/gt.2016.67. From NLM.","journal-title":"Gene Ther"},{"issue":"1","key":"3720_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","volume":"21","author":"SS Ali Zaidi","year":"2023","unstructured":"Ali Zaidi SS, Fatima F, Ali Zaidi SA, Zhou D, Deng W, Liu S. Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnology. 2023;21(1):381. https:\/\/doi.org\/10.1186\/s12951-023-02147-z.","journal-title":"J Nanobiotechnology"},{"key":"3720_CR36","doi-asserted-by":"publisher","unstructured":"Deng K, Yang D, Zhou, Y. Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy. Pharmaceutics. 2022;14(7). https:\/\/doi.org\/10.3390\/pharmaceutics14071344. From NLM.","DOI":"10.3390\/pharmaceutics14071344"},{"issue":"5","key":"3720_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s10142-024-01455-3","volume":"24","author":"J Rajanathadurai","year":"2024","unstructured":"Rajanathadurai J, Perumal E, Sindya J. Advances in targeting cancer epigenetics using CRISPR-dCas9 technology: a comprehensive review and future prospects. Funct Integr Genomics. 2024;24(5):164. https:\/\/doi.org\/10.1007\/s10142-024-01455-3. From NLM.","journal-title":"Funct Integr Genomics"},{"issue":"1","key":"3720_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther. 2023;8(1):69. https:\/\/doi.org\/10.1038\/s41392-023-01341-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3720_CR39","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1038\/srep08509","volume":"5","author":"X Yang","year":"2015","unstructured":"Yang X, Iyer AK, Singh A, Choy E, Hornicek FJ, Amiji MM, et al. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep. 2015;5(1):8509. https:\/\/doi.org\/10.1038\/srep08509.","journal-title":"Sci Rep"},{"key":"3720_CR40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","volume":"345","author":"JQ Liu","year":"2022","unstructured":"Liu JQ, Zhang C, Zhang X, Yan J, Zeng C, Talebian F, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Control Release. 2022;345:306\u201313. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.021. From NLM Medline.","journal-title":"J Control Release"},{"issue":"12","key":"3720_CR41","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"issue":"21","key":"3720_CR42","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.Can-07-6611","volume":"68","author":"VT DeVita Jr.","year":"2008","unstructured":"DeVita VT Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643\u201353. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-6611. Accessed 8\/10\/2025.","journal-title":"Cancer Res"},{"issue":"7","key":"3720_CR43","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/0360-301(85)90254-8","volume":"11","author":"J Einhorn","year":"1985","unstructured":"Einhorn J. Nitrogen mustard: the origin of chemotherapy for cancer. Int J Radiat Oncol Biol Phys. 1985;11(7):1375\u20138. https:\/\/doi.org\/10.1016\/0360-301(85)90254-8.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"3720_CR44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/nejm194806032382301","volume":"238","author":"S Farber","year":"1948","unstructured":"Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238(23):787\u201393. https:\/\/doi.org\/10.1056\/nejm194806032382301. From NLM.","journal-title":"N Engl J Med"},{"issue":"7","key":"3720_CR45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/mph.0000000000000206","volume":"36","author":"K Schmiegelow","year":"2014","unstructured":"Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine\/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36(7):503\u201317. https:\/\/doi.org\/10.1097\/mph.0000000000000206. From NLM.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"3720_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/1097-0142(197307)32:1<69::aid-cncr2820320109>3.0.co;2-0","volume":"32","author":"V Rodriguez","year":"1973","unstructured":"Rodriguez V, Hart JS, Freireich EJ, Bodey GP, McCredie KB, Whitecar JP Jr., et al. Pomp combination chemotherapy of adult acute leukemia. Cancer. 1973;32(1):69\u201375. https:\/\/doi.org\/10.1002\/1097-0142. From NLM.","journal-title":"Cancer"},{"issue":"7","key":"3720_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/op.21.00890","volume":"18","author":"P Torka","year":"2022","unstructured":"Torka P, Przespolewski E, Evens AM. Treatment strategies for advanced classical Hodgkin lymphoma in the times of Dacarbazine shortage. JCO Oncol Pract. 2022;18(7):491\u20137. https:\/\/doi.org\/10.1200\/op.21.00890.","journal-title":"JCO Oncol Pract"},{"issue":"21","key":"3720_CR48","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","volume":"327","author":"GP Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478\u201384. https:\/\/doi.org\/10.1056\/NEJM199211193272102.","journal-title":"N Engl J Med"},{"issue":"5","key":"3720_CR49","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12(5):2115\u201332. https:\/\/doi.org\/10.7150\/thno.69424. From NLM.","journal-title":"Theranostics"},{"issue":"2","key":"3720_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/07853899509031953","volume":"27","author":"JR Woodhouse","year":"1995","unstructured":"Woodhouse JR, Ferry DR. The genetic basis of resistance to cancer chemotherapy. Ann Med. 1995;27(2):157\u201367. https:\/\/doi.org\/10.3109\/07853899509031953. From NLM.","journal-title":"Ann Med"},{"issue":"9","key":"3720_CR51","first-page":"3643","volume":"44","author":"JH Goldie","year":"1984","unstructured":"Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 1984;44(9):3643\u201353. Accessed 8\/11\/2025.","journal-title":"Cancer Res"},{"issue":"1","key":"3720_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152\u201362. https:\/\/doi.org\/10.1016\/0005-2736(76)90160-7. From NLM.","journal-title":"Biochim Biophys Acta"},{"key":"3720_CR53","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615\u201327. https:\/\/doi.org\/10.1146\/annurev.med.53.082901.103929. From NLM.","journal-title":"Annu Rev Med"},{"issue":"9","key":"3720_CR54","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","volume":"9","author":"MB Meads","year":"2009","unstructured":"Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9(9):665\u201374. https:\/\/doi.org\/10.1038\/nrc2714. From NLM.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3720_CR55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275\u201384. https:\/\/doi.org\/10.1038\/nrc1590. From NLM.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3720_CR56","doi-asserted-by":"publisher","first-page":"930","DOI":"10.20517\/cdr.2020.68","volume":"3","author":"I Hassanin","year":"2020","unstructured":"Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist. 2020;3(4):930\u201346. https:\/\/doi.org\/10.20517\/cdr.2020.68. From NLM.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"3720_CR57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13148-025-01856-6","volume":"17","author":"H Zhang","year":"2025","unstructured":"Zhang H, Pang Y, Yi L, Wang X, Wei P, Wang H, et al. Epigenetic regulators combined with tumour immunotherapy: current status and perspectives. Clin Epigenetics. 2025;17(1):51. https:\/\/doi.org\/10.1186\/s13148-025-01856-6. From NLM.","journal-title":"Clin Epigenetics"},{"issue":"10","key":"3720_CR58","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/s2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724\u201336. https:\/\/doi.org\/10.1016\/s2352-3026(20)30210-6. From NLM.","journal-title":"Lancet Haematol"},{"issue":"1","key":"3720_CR59","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5732\/cjc.014.10289","volume":"34","author":"B Cheaib","year":"2015","unstructured":"Cheaib B, Auguste A, Leary A. The PI3K\/Akt\/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer. 2015;34(1):4\u201316. https:\/\/doi.org\/10.5732\/cjc.014.10289. From NLM.","journal-title":"Chin J Cancer"},{"key":"3720_CR60","doi-asserted-by":"publisher","first-page":"149352","DOI":"10.1016\/j.gene.2025.149352","volume":"948","author":"M Agrawal","year":"2025","unstructured":"Agrawal M, Agrawal SK, Chopra K. Overcoming drug resistance in ovarian cancer through PI3K\/AKT signaling inhibitors. Gene. 2025;948:149352. https:\/\/doi.org\/10.1016\/j.gene.2025.149352.","journal-title":"Gene"},{"key":"3720_CR61","doi-asserted-by":"publisher","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, et al. Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget. 2012;3(10). https:\/\/doi.org\/10.18632\/oncotarget.659.","DOI":"10.18632\/oncotarget.659"},{"issue":"1","key":"3720_CR62","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1186\/s12885-019-5824-9","volume":"19","author":"J Deng","year":"2019","unstructured":"Deng J, Bai X, Feng X, Ni J, Beretov J, Graham P, et al. Inhibition of PI3K\/Akt\/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer. 2019;19(1):618. https:\/\/doi.org\/10.1186\/s12885-019-5824-9. From NLM.","journal-title":"BMC Cancer"},{"key":"3720_CR63","doi-asserted-by":"publisher","unstructured":"Xiao M, He J, Yin L, Chen X, Zu X, Shen Y. Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer. Front Immunol. 2021;12.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2021.799428. Review.","DOI":"10.3389\/fimmu.2021.799428"},{"key":"3720_CR64","doi-asserted-by":"publisher","unstructured":"Lee S, Rauch J, Kolch W. Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. Int J Mol Sci. 2020;21(3). https:\/\/doi.org\/10.3390\/ijms21031102. From NLM.","DOI":"10.3390\/ijms21031102"},{"issue":"4","key":"3720_CR65","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.molcel.2019.05.036","volume":"75","author":"C Colomer","year":"2019","unstructured":"Colomer C, Margalef P, Villanueva A, Vert A, Pecharroman I, Sol\u00e9 L, et al. IKK\u03b1 Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer. Mol Cell. 2019;75(4):669-682.e665. https:\/\/doi.org\/10.1016\/j.molcel.2019.05.036.","journal-title":"Mol Cell"},{"key":"3720_CR66","doi-asserted-by":"publisher","unstructured":"Zhu GX, Gao D, Shao ZZ, Chen L, Ding WJ, Yu QF. Wnt\/\u03b2\u2011catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review). Mol Med Rep. 2021;23(2). https:\/\/doi.org\/10.3892\/mmr.2020.11744. From NLM.","DOI":"10.3892\/mmr.2020.11744"},{"key":"3720_CR67","doi-asserted-by":"publisher","first-page":"9390878","DOI":"10.1155\/2020\/9390878","volume":"2020","author":"S Yuan","year":"2020","unstructured":"Yuan S, Tao F, Zhang X, Zhang Y, Sun X, Wu D. Role of Wnt\/\u03b2-Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer. Biomed Res Int. 2020;2020:9390878. https:\/\/doi.org\/10.1155\/2020\/9390878. From NLM.","journal-title":"Biomed Res Int"},{"issue":"2","key":"3720_CR68","doi-asserted-by":"publisher","first-page":"297","DOI":"10.20517\/cdr.2018.11","volume":"2","author":"P Logeswari","year":"2019","unstructured":"Logeswari P, Prathap Kumar SM, Yu-Wei C, Kamaleshwar PS. Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer. Cancer Drug Resistance. 2019;2(2):297\u2013312. https:\/\/doi.org\/10.20517\/cdr.2018.11.","journal-title":"Cancer Drug Resistance"},{"key":"3720_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071586","author":"DA Senthebane","year":"2017","unstructured":"Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi M, et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18071586. From NLM.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3720_CR70","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275\u201392. https:\/\/doi.org\/10.1002\/path.1706. From NLM.","journal-title":"J Pathol"},{"key":"3720_CR71","doi-asserted-by":"publisher","unstructured":"Zhang XZ, Liu H, Chen SR. Mechanisms of Long Non-Coding RNAs in Cancers and Their Dynamic Regulations. Cancers (Basel). 2020;12(5). https:\/\/doi.org\/10.3390\/cancers12051245. From NLM.","DOI":"10.3390\/cancers12051245"},{"key":"3720_CR72","doi-asserted-by":"publisher","unstructured":"Zhang Y, Xu Y, Zhang Y, Wang S, Zhao M. The multiple functions and mechanisms of long non-coding RNAs in regulating breast cancer progression. Front Pharmacol. 2025;16.\u00a0https:\/\/doi.org\/10.3389\/fphar.2025.1559408. Review.","DOI":"10.3389\/fphar.2025.1559408"},{"issue":"3\u20134","key":"3720_CR73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10495-019-01588-y","volume":"25","author":"Y Chen","year":"2020","unstructured":"Chen Y, Song Y, Mi Y, Jin H, Cao J, Li H, et al. microRNA-499a promotes the progression and chemoresistance of cervical cancer cells by targeting SOX6. Apoptosis. 2020;25(3\u20134):205\u201316. https:\/\/doi.org\/10.1007\/s10495-019-01588-y. From NLM.","journal-title":"Apoptosis"},{"key":"3720_CR74","doi-asserted-by":"publisher","first-page":"113345","DOI":"10.1016\/j.biopha.2022.113345","volume":"153","author":"R Bhattacharjee","year":"2022","unstructured":"Bhattacharjee R, Dey T, Kumar L, Kar S, Sarkar R, Ghorai M, et al. Cellular landscaping of cisplatin resistance in cervical cancer. Biomed Pharmacother. 2022;153:113345. https:\/\/doi.org\/10.1016\/j.biopha.2022.113345.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3720_CR75","doi-asserted-by":"publisher","first-page":"A27","DOI":"10.1186\/1471-2407-7-S1-A27","volume":"7","author":"M Candelaria","year":"2007","unstructured":"Candelaria M, Gallardo-Rinc\u00f3n D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. BMC Cancer. 2007;7(1):A27. https:\/\/doi.org\/10.1186\/1471-2407-7-S1-A27.","journal-title":"BMC Cancer"},{"issue":"11","key":"3720_CR76","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.2174\/13816128113199990512","volume":"20","author":"Y Lin","year":"2014","unstructured":"Lin Y, Dong C, Zhou BP. Epigenetic regulation of EMT: the Snail story. Curr Pharm Des. 2014;20(11):1698\u2013705. https:\/\/doi.org\/10.2174\/13816128113199990512. From NLM.","journal-title":"Curr Pharm Des"},{"issue":"20","key":"3720_CR77","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1007\/s00018-012-1122-2","volume":"69","author":"E S\u00e1nchez-Till\u00f3","year":"2012","unstructured":"S\u00e1nchez-Till\u00f3 E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci. 2012;69(20):3429\u201356. https:\/\/doi.org\/10.1007\/s00018-012-1122-2. From NLM.","journal-title":"Cell Mol Life Sci"},{"key":"3720_CR78","doi-asserted-by":"publisher","unstructured":"Wu Y-H, Huang Y-F, Chen C-C, Huang C-Y, Chou, C-Y. Comparing PI3K\/Akt Inhibitors Used in Ovarian Cancer Treatment. Front Pharmacol. 2020;11.\u00a0https:\/\/doi.org\/10.3389\/fphar.2020.00206. Original Research.","DOI":"10.3389\/fphar.2020.00206"},{"issue":"3","key":"3720_CR79","doi-asserted-by":"publisher","first-page":"573","DOI":"10.20517\/cdr.2021.05","volume":"4","author":"R Natasha","year":"2021","unstructured":"Natasha R, Elizabeth LC, Anastasia A, Chun Hei K, Nikita D, Caroline L, et al. Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resistance. 2021;4(3):573\u201395. https:\/\/doi.org\/10.20517\/cdr.2021.05.","journal-title":"Cancer Drug Resistance"},{"issue":"1","key":"3720_CR80","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","volume":"17","author":"P Song","year":"2024","unstructured":"Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y, et al. Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy. J Hematol Oncol. 2024;17(1):46. https:\/\/doi.org\/10.1186\/s13045-024-01563-4. From NLM.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3720_CR81","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt\/\u03b2-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6(1):307. https:\/\/doi.org\/10.1038\/s41392-021-00701-5.","journal-title":"Signal Transduct Target Ther"},{"key":"3720_CR82","doi-asserted-by":"publisher","unstructured":"Doktorova H, Hrabeta J, Khalil MA, Eckschlager T. Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015, 159;(2):166\u201377. https:\/\/doi.org\/10.5507\/bp.2015.025.","DOI":"10.5507\/bp.2015.025"},{"key":"3720_CR83","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bioactmat.2021.12.029","volume":"16","author":"T Wang","year":"2022","unstructured":"Wang T, Zhang H, Qiu W, Han Y, Liu H, Li Z. Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy. Bioact Mater. 2022;16:418\u201332. https:\/\/doi.org\/10.1016\/j.bioactmat.2021.12.029.","journal-title":"Bioact Mater"},{"key":"3720_CR84","doi-asserted-by":"publisher","unstructured":"Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022;132(11). https:\/\/doi.org\/10.1172\/jci159839. From NLM.","DOI":"10.1172\/jci159839"},{"issue":"1","key":"3720_CR85","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13046-020-01733-5","volume":"39","author":"T Li","year":"2020","unstructured":"Li T, Mao C, Wang X, Shi Y, Tao Y. Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation. J Exp Clin Cancer Res. 2020;39(1):224. https:\/\/doi.org\/10.1186\/s13046-020-01733-5.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3720_CR86","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12951-025-03134-2","volume":"23","author":"Q Gong","year":"2025","unstructured":"Gong Q, Song X, Tong Y, Huo L, Zhao X, Han Y, et al. Recent advances of anti-tumor nano-strategies via overturning pH gradient: alkalization and acidification. J Nanobiotechnology. 2025;23(1):42. https:\/\/doi.org\/10.1186\/s12951-025-03134-2.","journal-title":"J Nanobiotechnology"},{"issue":"10","key":"3720_CR87","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc.2017.77","volume":"17","author":"C Corbet","year":"2017","unstructured":"Corbet C, Feron O. Tumour acidosis: from the passenger to the driver\u2019s seat. Nat Rev Cancer. 2017;17(10):577\u201393. https:\/\/doi.org\/10.1038\/nrc.2017.77.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3720_CR88","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1002\/ijc.23818","volume":"123","author":"C Sauvant","year":"2008","unstructured":"Sauvant C, Nowak M, Wirth C, Schneider B, Riemann A, Gekle M, et al. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int J Cancer. 2008;123(11):2532\u201342. https:\/\/doi.org\/10.1002\/ijc.23818. From NLM.","journal-title":"Int J Cancer"},{"issue":"11","key":"3720_CR89","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1093\/nar\/gks066","volume":"40","author":"T Latham","year":"2012","unstructured":"Latham T, Mackay L, Sproul D, Karim M, Culley J, Harrison DJ, et al. Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Res. 2012;40(11):4794\u2013803. https:\/\/doi.org\/10.1093\/nar\/gks066. From NLM.","journal-title":"Nucleic Acids Res"},{"key":"3720_CR90","doi-asserted-by":"publisher","unstructured":"Cao L, Huang T, Chen X, Li W, Yang X, Zhang W, Li M, Gao R. Uncovering the interplay between pH receptors and immune cells: Potential drug targets (Review). Oncol Rep. 2021;46(4). https:\/\/doi.org\/10.3892\/or.2021.8179. From NLM.","DOI":"10.3892\/or.2021.8179"},{"issue":"23","key":"3720_CR91","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1158\/1078-0432.Ccr-17-1283","volume":"23","author":"Y Yin","year":"2017","unstructured":"Yin Y, Yao S, Hu Y, Feng Y, Li M, Bian Z, et al. The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6. Clin Cancer Res. 2017;23(23):7375\u201387. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-1283. From NLM.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3720_CR92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. npj Precis Oncol. 2024;8(1):31. https:\/\/doi.org\/10.1038\/s41698-024-00522-z.","journal-title":"npj Precis Oncol"},{"issue":"39","key":"3720_CR93","doi-asserted-by":"publisher","first-page":"5854","DOI":"10.1038\/s41388-021-01986-0","volume":"40","author":"F Zhang","year":"2021","unstructured":"Zhang F, Li P, Liu S, Yang M, Zeng S, Deng J, et al. \u03b2-Catenin-CCL2 feedback loop mediates crosstalk between cancer cells and macrophages that regulates breast cancer stem cells. Oncogene. 2021;40(39):5854\u201365. https:\/\/doi.org\/10.1038\/s41388-021-01986-0.","journal-title":"Oncogene"},{"key":"3720_CR94","doi-asserted-by":"publisher","unstructured":"Shi S, Ou X, Liu C, Li R, Zheng Q, Hu L. NF-\u03baB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance. Front Immunol. 2025;16.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2025.1518664. Review.","DOI":"10.3389\/fimmu.2025.1518664"},{"issue":"18","key":"3720_CR95","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1158\/0008-5472.CAN-17-0072","volume":"77","author":"K-H Song","year":"2017","unstructured":"Song K-H, Choi CH, Lee H-J, Oh SJ, Woo SR, Hong S-O, et al. HDAC1 upregulation by NANOG promotes multidrug resistance and a stem-like phenotype in immune edited tumor cells. Cancer Res. 2017;77(18):5039\u201353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0072. Accessed 8\/23\/2025.","journal-title":"Cancer Res"},{"key":"3720_CR96","doi-asserted-by":"publisher","first-page":"939249","DOI":"10.3389\/fonc.2022.939249","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhou C, Zhang S, Chen X, Liu J, Xu F, et al. Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Front Oncol. 2022;12:939249. https:\/\/doi.org\/10.3389\/fonc.2022.939249. From NLM.","journal-title":"Front Oncol"},{"issue":"1","key":"3720_CR97","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13058-019-1231-z","volume":"21","author":"BV Sinn","year":"2019","unstructured":"Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, et al. Human leucocyte antigen class i in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res. 2019;21(1):142. https:\/\/doi.org\/10.1186\/s13058-019-1231-z. From NLM.","journal-title":"Breast Cancer Res"},{"issue":"15","key":"3720_CR98","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1158\/1078-0432.Ccr-19-0173","volume":"25","author":"AG Waks","year":"2019","unstructured":"Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clin Cancer Res. 2019;25(15):4644\u201355. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0173. From NLM.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3720_CR99","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Waschke BC, Woolaver RA, Chen SMY, Chen Z, Wang JH. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell. 2020;11(7):472\u201382. https:\/\/doi.org\/10.1007\/s13238-020-00694-x. Accessed 7\/30\/2025.","journal-title":"Protein Cell"},{"key":"3720_CR100","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-1-4020-9576-4_5","volume-title":"Cancer Microenvironment and Therapeutic Implications: Tumor Pathophysiology Mechanisms and Therapeutic Strategies","author":"G Baronzio","year":"2009","unstructured":"Baronzio G, Freitas I, Baronzio A, Baronzio M, Crespi E, Netti PA. Barriers to Drug Delivery in Cancer: Clinical Implications. In: Baronzio G, Fiorentini G, Cogle CR, editors. Cancer Microenvironment and Therapeutic Implications: Tumor Pathophysiology Mechanisms and Therapeutic Strategies. Netherlands: Springer; 2009. p. 81\u2013104."},{"issue":"3","key":"3720_CR101","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ccr.2005.08.010","volume":"8","author":"MJ Paszek","year":"2005","unstructured":"Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8(3):241\u201354. https:\/\/doi.org\/10.1016\/j.ccr.2005.08.010.","journal-title":"Cancer Cell"},{"issue":"1","key":"3720_CR102","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","volume":"14","author":"M Zhang","year":"2025","unstructured":"Zhang M, Zhang B. Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer. Exp Hematol Oncol. 2025;14(1):54. https:\/\/doi.org\/10.1186\/s40164-025-00647-2. From NLM.","journal-title":"Exp Hematol Oncol"},{"issue":"20","key":"3720_CR103","doi-asserted-by":"publisher","first-page":"e2021571118","DOI":"10.1073\/pnas.2021571118","volume":"118","author":"KE Scott","year":"2021","unstructured":"Scott KE, Fraley SI, Rangamani P. A spatial model of YAP\/TAZ signaling reveals how stiffness, dimensionality, and shape contribute to emergent outcomes. Proc Natl Acad Sci. 2021;118(20):e2021571118. https:\/\/doi.org\/10.1073\/pnas.2021571118. Accessed 2025\/08\/02.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"3720_CR104","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41540-024-00414-9","volume":"10","author":"H Jafarinia","year":"2024","unstructured":"Jafarinia H, Khalilimeybodi A, Barrasa-Fano J, Fraley SI, Rangamani P, Carlier A. Insights gained from computational modeling of YAP\/TAZ signaling for cellular mechanotransduction. npj Syst Biol Appl. 2024;10(1):90. https:\/\/doi.org\/10.1038\/s41540-024-00414-9.","journal-title":"npj Syst Biol Appl"},{"issue":"39","key":"3720_CR105","doi-asserted-by":"publisher","first-page":"32800","DOI":"10.1074\/jbc.M111.308528","volume":"287","author":"LY Bourguignon","year":"2012","unstructured":"Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2012;287(39):32800\u201324. https:\/\/doi.org\/10.1074\/jbc.M111.308528. From NLM.","journal-title":"J Biol Chem"},{"key":"3720_CR106","doi-asserted-by":"publisher","unstructured":"Ooki T, Hayashi T, Yamamoto Y, Hatakeyama M. YAP1-2\u03b1\/TAZ heterodimerization drives phase separation, activating TEAD-positive super-enhancers that enhance cancer stemness and multidrug resistance. bioRxiv 2025, 2025.2001.2028.635202. https:\/\/doi.org\/10.1101\/2025.01.28.635202.","DOI":"10.1101\/2025.01.28.635202"},{"key":"3720_CR107","doi-asserted-by":"publisher","unstructured":"Kaarij\u00e4rvi R, Kaljunen H, Niemi O, R\u00e4s\u00e4nen M, Paakinaho V, Ketola K. Matrix stiffness modulates androgen response genes and chromatin state in prostate cancer. NAR Cancer. 2025;7(1). https:\/\/doi.org\/10.1093\/narcan\/zcaf010. Accessed 8\/15\/2025.","DOI":"10.1093\/narcan\/zcaf010"},{"key":"3720_CR108","doi-asserted-by":"publisher","first-page":"100793","DOI":"10.1016\/j.neo.2022.100793","volume":"30","author":"T Seki","year":"2022","unstructured":"Seki T, Saida Y, Kishimoto S, Lee J, Otowa Y, Yamamoto K, et al. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study. Neoplasia. 2022;30:100793. https:\/\/doi.org\/10.1016\/j.neo.2022.100793. From NLM.","journal-title":"Neoplasia"},{"key":"3720_CR109","doi-asserted-by":"publisher","unstructured":"Huang M, Wang H, Mackey C, Chung MC, Guan J, Zheng G, Roy A, Xie M, Vulpe C, Tang X. YAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer. Int J Mol Sci. 2023;24(15). https:\/\/doi.org\/10.3390\/ijms241512491. From NLM.","DOI":"10.3390\/ijms241512491"},{"issue":"1","key":"3720_CR110","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s11033-025-10296-7","volume":"52","author":"J Aakriti","year":"2025","unstructured":"Aakriti J, Vithalkar MP, Maity S, Baby K, Nagareddy PR, Nayak Y. Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors. Mol Biol Rep. 2025;52(1):248. https:\/\/doi.org\/10.1007\/s11033-025-10296-7. From NLM.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"3720_CR111","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13058-025-02072-z","volume":"27","author":"CH Lee","year":"2025","unstructured":"Lee CH, Park SY, Lee JS, Kim DS, Kim HY, Song MJ, et al. MSN\/STAT3 drives cancer stemness and chemoresistance via IL-6\/LPAR1 ligand receptor complex in triple-negative breast cancer. Breast Cancer Res. 2025;27(1):136. https:\/\/doi.org\/10.1186\/s13058-025-02072-z. From NLM.","journal-title":"Breast Cancer Res"},{"key":"3720_CR112","doi-asserted-by":"publisher","first-page":"101901","DOI":"10.1016\/j.tranon.2024.101901","volume":"42","author":"A Kar","year":"2024","unstructured":"Kar A, Agarwal S, Singh A, Bajaj A, Dasgupta U. Insights into molecular mechanisms of chemotherapy resistance in cancer. Transl Oncol. 2024;42:101901. https:\/\/doi.org\/10.1016\/j.tranon.2024.101901.","journal-title":"Transl Oncol"},{"issue":"1","key":"3720_CR113","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22(1):109. https:\/\/doi.org\/10.1186\/s12964-023-01302-1.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"3720_CR114","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s43556-024-00239-2","volume":"6","author":"Y Gu","year":"2025","unstructured":"Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M, et al. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Mol Biomed. 2025;6(1):2. https:\/\/doi.org\/10.1186\/s43556-024-00239-2. From NLM.","journal-title":"Mol Biomed"},{"key":"3720_CR115","doi-asserted-by":"publisher","unstructured":"Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. Mechanism of multidrug resistance to chemotherapy mediated by P\u2011glycoprotein (Review). Int J Oncol. 2023;63(5). https:\/\/doi.org\/10.3892\/ijo.2023.5567. From NLM.","DOI":"10.3892\/ijo.2023.5567"},{"issue":"7","key":"3720_CR116","first-page":"1937","volume":"10","author":"S Wang","year":"2020","unstructured":"Wang S, Li Y, Xing C, Ding C, Zhang H, Chen L, et al. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Am J Cancer Res. 2020;10(7):1937\u201353. From NLM.","journal-title":"Am J Cancer Res"},{"issue":"14","key":"3720_CR117","doi-asserted-by":"publisher","first-page":"13417","DOI":"10.1007\/s00432-023-05136-9","volume":"149","author":"D Dorna","year":"2023","unstructured":"Dorna D, Paluszczak J. Targeting cancer stem cells as a strategy for reducing chemotherapy resistance in head and neck cancers. J Cancer Res Clin Oncol. 2023;149(14):13417\u201335. https:\/\/doi.org\/10.1007\/s00432-023-05136-9. From NLM.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3720_CR118","doi-asserted-by":"publisher","first-page":"116647","DOI":"10.1016\/j.ejmech.2024.116647","volume":"276","author":"R Ibba","year":"2024","unstructured":"Ibba R, Sestito S, Ambrosio FA, Marchese E, Costa G, Fiorentino FP, et al. Discovery of pyridoquinoxaline-based new P-gp inhibitors as coadjutant against multi drug resistance in cancer. Eur J Med Chem. 2024;276:116647. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116647.","journal-title":"Eur J Med Chem"},{"key":"3720_CR119","doi-asserted-by":"publisher","first-page":"629266","DOI":"10.3389\/fphar.2020.629266","volume":"11","author":"LY Li","year":"2020","unstructured":"Li LY, Guan YD, Chen XS, Yang JM, Cheng Y. DNA repair pathways in cancer therapy and resistance. Front Pharmacol. 2020;11:629266. https:\/\/doi.org\/10.3389\/fphar.2020.629266. From NLM.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3720_CR120","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s12672-025-02567-3","volume":"16","author":"J Pu","year":"2025","unstructured":"Pu J, Yuan K, Tao J, Qin Y, Li Y, Fu J, et al. Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance. Discov Oncol. 2025;16(1):731. https:\/\/doi.org\/10.1007\/s12672-025-02567-3. From NLM.","journal-title":"Discov Oncol"},{"key":"3720_CR121","doi-asserted-by":"publisher","unstructured":"Dhiman VK, Kumari M, Singh D, Lyu P. Chemoresistance: The hidden barrier in cancer treatment. Cancer Pathogen Ther. https:\/\/doi.org\/10.1016\/j.cpt.2025.07.001.","DOI":"10.1016\/j.cpt.2025.07.001"},{"key":"3720_CR122","unstructured":"Daoudi, R. Understanding AKT-mediated chemoresistance: the relationship between ion channels and AKT activation. arXiv preprint arXiv:2307.07427. 2023."},{"issue":"1","key":"3720_CR123","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12964-024-01857-7","volume":"22","author":"B Wilczy\u0144ski","year":"2024","unstructured":"Wilczy\u0144ski B, D\u0105browska A, Kulbacka J, Baczy\u0144ska D. Chemoresistance and the tumor microenvironment: the critical role of cell-cell communication. Cell Commun Signal. 2024;22(1):486. . https:\/\/doi.org\/10.1186\/s12964-024-01857-7","journal-title":"Cell Commun Signal"},{"key":"3720_CR124","doi-asserted-by":"publisher","unstructured":"Chen F, Fu Y, Bai G, Qiu J, Hua K. Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming. Front Pharmacol. 2025;16.\u00a0https:\/\/doi.org\/10.3389\/fphar.2025.1634413. Review.","DOI":"10.3389\/fphar.2025.1634413"},{"issue":"4","key":"3720_CR125","first-page":"482","volume":"1","author":"P Cirri","year":"2011","unstructured":"Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011;1(4):482\u201397. From NLM.","journal-title":"Am J Cancer Res"},{"key":"3720_CR126","doi-asserted-by":"publisher","unstructured":"Wang J, Cao W, Huang J, Zhou Y, Zheng R, Lou Y, Yang J, Yan J, Tang J, Ye M, et al. Tumor-associated CD19(+) macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma. Nat Commun 2026;17(1):3250. https:\/\/doi.org\/10.1038\/s41467-026-69638-z.","DOI":"10.1038\/s41467-026-69638-z"},{"key":"3720_CR127","doi-asserted-by":"publisher","unstructured":"Khalaf K, Hana D, Chou JT-T, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance. Front Immunol. 2021;12.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2021.656364. Review.","DOI":"10.3389\/fimmu.2021.656364"},{"key":"3720_CR128","doi-asserted-by":"publisher","unstructured":"Tufail M, Hu J-J, Liang J, He C-Y, Wan W-D, Huang Y-Q, Jiang C-H, Wu H, Li N. Hallmarks of cancer resistance. iScience. 2024;27(6). https:\/\/doi.org\/10.1016\/j.isci.2024.109979. Accessed 2025\/08\/03.","DOI":"10.1016\/j.isci.2024.109979"},{"issue":"1","key":"3720_CR129","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13287-022-02856-6","volume":"13","author":"H Rezayatmand","year":"2022","unstructured":"Rezayatmand H, Razmkhah M, Razeghian-Jahromi I. Drug resistance in cancer therapy: the Pandora\u2019s Box of cancer stem cells. Stem Cell Res Ther. 2022;13(1):181. https:\/\/doi.org\/10.1186\/s13287-022-02856-6.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"3720_CR130","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1210\/endrev\/bnad001","volume":"44","author":"A Komarla","year":"2023","unstructured":"Komarla A, Dufresne S, Towers CG. Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors. Endocr Rev. 2023;44(4):629\u201346. https:\/\/doi.org\/10.1210\/endrev\/bnad001. Accessed8\/3\/2025.","journal-title":"Endocr Rev"},{"issue":"7955","key":"3720_CR131","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05838-7","volume":"616","author":"M Debaugnies","year":"2023","unstructured":"Debaugnies M, Rodr\u00edguez-Acebes S, Blondeau J, Parent M-A, Zocco M, Song Y, et al. RHOJ controls EMT-associated resistance to chemotherapy. Nature. 2023;616(7955):168\u201375. https:\/\/doi.org\/10.1038\/s41586-023-05838-7.","journal-title":"Nature"},{"issue":"7","key":"3720_CR132","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00204-021-03063-7","volume":"95","author":"J De Las Rivas","year":"2021","unstructured":"De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95(7):2279\u201397. https:\/\/doi.org\/10.1007\/s00204-021-03063-7. From NLM.","journal-title":"Arch Toxicol"},{"issue":"6","key":"3720_CR133","doi-asserted-by":"publisher","first-page":"e1662","DOI":"10.1002\/wrna.1662","volume":"12","author":"LF Sempere","year":"2021","unstructured":"Sempere LF, Azmi AS, Moore A. microRNA-based diagnostic and therapeutic applications in cancer medicine. Wiley Interdiscip Rev RNA. 2021;12(6):e1662. https:\/\/doi.org\/10.1002\/wrna.1662. From NLM.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"3720_CR134","doi-asserted-by":"publisher","unstructured":"Kousar K, Ahmad T, Abduh MS, Kanwal B, Shah SS, Naseer F, Anjum S. miRNAs in Regulation of Tumor Microenvironment, Chemotherapy Resistance, Immunotherapy Modulation and miRNA Therapeutics in Cancer. Int J Mol Sci. 2022;23(22). https:\/\/doi.org\/10.3390\/ijms232213822. From NLM.","DOI":"10.3390\/ijms232213822"},{"issue":"1","key":"3720_CR135","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-022-00975-3","volume":"7","author":"B Chen","year":"2022","unstructured":"Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 2022;7(1):121. https:\/\/doi.org\/10.1038\/s41392-022-00975-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"3720_CR136","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s12032-025-03006-7","volume":"42","author":"MM Mostafa","year":"2025","unstructured":"Mostafa MM, El-Aziz MKA, Ellakwa DE. miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression. Med Oncol. 2025;42(10):454. https:\/\/doi.org\/10.1007\/s12032-025-03006-7. From NLM.","journal-title":"Med Oncol"},{"issue":"1","key":"3720_CR137","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12935-023-02929-3","volume":"23","author":"MJ Iqbal","year":"2023","unstructured":"Iqbal MJ, Javed Z, Sadia H, Mehmood S, Akbar A, Zahid B, et al. Targeted therapy using nanocomposite delivery systems in cancer treatment: highlighting miR34a regulation for clinical applications. Cancer Cell Int. 2023;23(1):84. https:\/\/doi.org\/10.1186\/s12935-023-02929-3. From NLM.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"3720_CR138","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13148-025-01961-6","volume":"17","author":"X Yu","year":"2025","unstructured":"Yu X, Jia L, Tang Q, Zhou Q, Wang G, Wang S. Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms. Clin Epigenetics. 2025;17(1):145. https:\/\/doi.org\/10.1186\/s13148-025-01961-6. From NLM.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"3720_CR139","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1186\/s12967-025-06959-5","volume":"23","author":"Y Shou","year":"2025","unstructured":"Shou Y, Liu R, Xiong H, Chen X, Huang L, Huang R, et al. Lactylation-mediated miRNA regulation in cancer therapy resistance. J Transl Med. 2025;23(1):941. https:\/\/doi.org\/10.1186\/s12967-025-06959-5. From NLM.","journal-title":"J Transl Med"},{"key":"3720_CR140","doi-asserted-by":"publisher","first-page":"653037","DOI":"10.3389\/fonc.2021.653037","volume":"11","author":"F Wang","year":"2021","unstructured":"Wang F, Malnassy G, Qiu W. The Epigenetic Regulation of Microenvironment in Hepatocellular Carcinoma. Front Oncol. 2021;11:653037. https:\/\/doi.org\/10.3389\/fonc.2021.653037. From NLM.","journal-title":"Front Oncol"},{"key":"3720_CR141","doi-asserted-by":"publisher","first-page":"384","DOI":"10.17179\/excli2023-6404","volume":"23","author":"M Abdoli Shadbad","year":"2024","unstructured":"Abdoli Shadbad M, Baghbanzadeh A, Baradaran B. hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma: in-silico and in-vitro study. EXCLI J. 2024;23:384\u2013400. https:\/\/doi.org\/10.17179\/excli2023-6404. From NLM.","journal-title":"EXCLI J"},{"issue":"24","key":"3720_CR142","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1039\/d4na00660g","volume":"6","author":"A Verma","year":"2024","unstructured":"Verma A, Patel K, Kumar A. Targeting drug resistance in breast cancer: the potential of miRNA and nanotechnology-driven delivery systems. Nanoscale Adv. 2024;6(24):6079\u201395. https:\/\/doi.org\/10.1039\/d4na00660g. From NLM.","journal-title":"Nanoscale Adv"},{"key":"3720_CR143","doi-asserted-by":"publisher","unstructured":"Kara G, Arun B, Calin GA, Ozpolat B. miRacle of microRNA-Driven Cancer Nanotherapeutics. Cancers (Basel). 2022;14(15). https:\/\/doi.org\/10.3390\/cancers14153818. From NLM.","DOI":"10.3390\/cancers14153818"},{"key":"3720_CR144","doi-asserted-by":"publisher","unstructured":"Reda El Sayed S, Cristante J, Guyon L, Denis J, Chabre O, Cherradi N. MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers (Basel). 2021;13(11). https:\/\/doi.org\/10.3390\/cancers13112680. From NLM.","DOI":"10.3390\/cancers13112680"},{"issue":"7","key":"3720_CR145","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","volume":"55","author":"T Kim","year":"2023","unstructured":"Kim T, Croce CM. MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp Mol Med. 2023;55(7):1314\u201321. https:\/\/doi.org\/10.1038\/s12276-023-01050-9. PubMed.","journal-title":"Exp Mol Med"},{"issue":"21","key":"3720_CR146","doi-asserted-by":"publisher","first-page":"10794","DOI":"10.3390\/ijms262110794","volume":"26","author":"RD Brata","year":"2025","unstructured":"Brata RD, Marcut L, Barb AC, Manole A, Ciolofan A, Dumitru CS, et al. MicroRNAs as emerging therapeutic targets modulating the tumor microenvironment in head and neck squamous cell carcinoma. Int J Mol Sci. 2025;26(21):10794.","journal-title":"Int J Mol Sci"},{"key":"3720_CR147","doi-asserted-by":"publisher","first-page":"64","DOI":"10.20517\/cdr.2025.146","volume":"8","author":"M Attathikhun","year":"2025","unstructured":"Attathikhun M, Jurj A, Calin GA. MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy. Cancer Drug Resist. 2025;8:64. https:\/\/doi.org\/10.20517\/cdr.2025.146. From NLM.","journal-title":"Cancer Drug Resist"},{"key":"3720_CR148","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40824-018-0132-z","volume":"22","author":"S Uthaman","year":"2018","unstructured":"Uthaman S, Huh KM, Park IK. Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications. Biomater Res. 2018;22:22. https:\/\/doi.org\/10.1186\/s40824-018-0132-z. From NLM.","journal-title":"Biomater Res"},{"key":"3720_CR149","doi-asserted-by":"publisher","first-page":"7987","DOI":"10.2147\/ijn.S526497","volume":"20","author":"H Sun","year":"2025","unstructured":"Sun H, Li Y, Xue M, Feng D. Tumor microenvironment-responsive nanoparticles: promising cancer PTT carriers. Int J Nanomedicine. 2025;20:7987\u20138001. https:\/\/doi.org\/10.2147\/ijn.S526497. From NLM.","journal-title":"Int J Nanomedicine"},{"key":"3720_CR150","doi-asserted-by":"publisher","unstructured":"Liu H, Yao J, Guo H, Cai X, Jiang Y, Lin M, Jiang X, Leung W, Xu C. Tumor Microenvironment-Responsive Nanomaterials as Targeted Delivery Carriers for Photodynamic Anticancer Therapy. Front Chem. 2020;8.\u00a0https:\/\/doi.org\/10.3389\/fchem.2020.00758. Mini Review.","DOI":"10.3389\/fchem.2020.00758"},{"key":"3720_CR151","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2019.12.041","volume":"319","author":"R Kumari","year":"2020","unstructured":"Kumari R, Sunil D, Ningthoujam RS. Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: an up-to-date review. J Control Release. 2020;319:135\u201356. https:\/\/doi.org\/10.1016\/j.jconrel.2019.12.041. From NLM.","journal-title":"J Control Release"},{"key":"3720_CR152","doi-asserted-by":"publisher","first-page":"1089446","DOI":"10.3389\/fonc.2022.1089446","volume":"12","author":"Y Xia","year":"2022","unstructured":"Xia Y, Duan S, Han C, Jing C, Xiao Z, Li C. Hypoxia-responsive nanomaterials for tumor imaging and therapy. Front Oncol. 2022;12:1089446. https:\/\/doi.org\/10.3389\/fonc.2022.1089446. From NLM.","journal-title":"Front Oncol"},{"issue":"1","key":"3720_CR153","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.addr.2010.05.006","volume":"63","author":"M Mahmoudi","year":"2011","unstructured":"Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev. 2011;63(1):24\u201346. https:\/\/doi.org\/10.1016\/j.addr.2010.05.006.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"3720_CR154","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.rpor.2019.04.002","volume":"24","author":"M Musielak","year":"2019","unstructured":"Musielak M, Piotrowski I, Suchorska WM. Superparamagnetic iron oxide nanoparticles (SPIONs) as a multifunctional tool in various cancer therapies. Rep Pract Oncol Radiother. 2019;24(4):307\u201314. https:\/\/doi.org\/10.1016\/j.rpor.2019.04.002. From NLM.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"1","key":"3720_CR155","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s000180050495","volume":"57","author":"N Johansson","year":"2000","unstructured":"Johansson N, Ahonen M, K\u00e4h\u00e4ri V-M. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci. 2000;57(1):5\u201315.","journal-title":"Cell Mol Life Sci"},{"key":"3720_CR156","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.nano.2019.03.012","volume":"19","author":"Q Yao","year":"2019","unstructured":"Yao Q, Liu Y, Kou L, Tu Y, Tang X, Zhu L. Tumor-targeted drug delivery and sensitization by MMP2-responsive polymeric micelles. Nanomedicine. 2019;19:71\u201380. https:\/\/doi.org\/10.1016\/j.nano.2019.03.012. From NLM.","journal-title":"Nanomedicine"},{"key":"3720_CR157","doi-asserted-by":"publisher","first-page":"1115603","DOI":"10.3389\/fbioe.2023.1115603","volume":"11","author":"J Liu","year":"2023","unstructured":"Liu J, Jia B, Li Z, Li W. Reactive oxygen species-responsive polymer drug delivery systems. Front Bioeng Biotechnol. 2023;11:1115603. https:\/\/doi.org\/10.3389\/fbioe.2023.1115603. From NLM.","journal-title":"Front Bioeng Biotechnol"},{"key":"3720_CR158","doi-asserted-by":"publisher","unstructured":"Rinaldi A, Caraffi R, Grazioli MV, Oddone N, Giardino L, Tosi G, Vandelli MA, Calz\u00e0 L, Ruozi B, Duskey JT. Applications of the ROS-Responsive Thioketal Linker for the Production of Smart Nanomedicines. Polymers (Basel). 2022;14(4). https:\/\/doi.org\/10.3390\/polym14040687. From NLM.","DOI":"10.3390\/polym14040687"},{"issue":"13-14","key":"3720_CR159","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.addr.2013.09.001","volume":"65","author":"AR Kirtane","year":"2013","unstructured":"Kirtane AR, Kalscheuer SM, Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. Adv Drug Deliv Rev. 2013;65(13\u201314):1731\u201347. https:\/\/doi.org\/10.1016\/j.addr.2013.09.001. From NLM.","journal-title":"Adv Drug Deliv Rev"},{"issue":"21","key":"3720_CR160","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.drudis.2009.07.010","volume":"14","author":"T Bansal","year":"2009","unstructured":"Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today. 2009;14(21):1067\u201374. https:\/\/doi.org\/10.1016\/j.drudis.2009.07.010.","journal-title":"Drug Discov Today"},{"issue":"6","key":"3720_CR161","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/mp100253e","volume":"7","author":"W Gao","year":"2010","unstructured":"Gao W, Chan JM, Farokhzad OC. pH-responsive nanoparticles for drug delivery. Mol Pharm. 2010;7(6):1913\u201320. https:\/\/doi.org\/10.1021\/mp100253e. From NLM.","journal-title":"Mol Pharm"},{"key":"3720_CR162","doi-asserted-by":"publisher","first-page":"0148","DOI":"10.34133\/research.0148","volume":"6","author":"C Qiu","year":"2023","unstructured":"Qiu C, Xia F, Zhang J, Shi Q, Meng Y, Wang C, et al. Advanced strategies for overcoming endosomal\/lysosomal barrier in nanodrug delivery. Research. 2023;6:0148. https:\/\/doi.org\/10.34133\/research.0148.","journal-title":"Research"},{"issue":"12","key":"3720_CR163","first-page":"5782","volume":"11","author":"F Naz","year":"2021","unstructured":"Naz F, Shi M, Sajid S, Yang Z, Yu C. Cancer stem cells: a major culprit of intra-tumor heterogeneity. Am J Cancer Res. 2021;11(12):5782\u2013811. From NLM.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"3720_CR164","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/10717544.2021.1905748","volume":"28","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang T, Ma Q. Layer-by-layer assembled nano-drug delivery systems for cancer treatment. Drug Deliv. 2021;28(1):655\u201369. https:\/\/doi.org\/10.1080\/10717544.2021.1905748. From NLM.","journal-title":"Drug Deliv"},{"issue":"530","key":"3720_CR165","doi-asserted-by":"publisher","first-page":"eaax6337","DOI":"10.1126\/scitranslmed.aax6337","volume":"12","author":"JM Jaynes","year":"2020","unstructured":"Jaynes JM, Sable R, Ronzetti M, Bautista W, Knotts Z, Abisoye-Ogunniyan A, et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci Transl Med. 2020;12(530):eaax6337. https:\/\/doi.org\/10.1126\/scitranslmed.aax6337. From NLM Medline.","journal-title":"Sci Transl Med"},{"key":"3720_CR166","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","volume":"11","author":"W Zhang","year":"2020","unstructured":"Zhang W, Huang Q, Xiao W, Zhao Y, Pi J, Xu H, et al. Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 axis. Front Immunol. 2020;11:18. https:\/\/doi.org\/10.3389\/fimmu.2020.00018. From NLM.","journal-title":"Front Immunol"},{"issue":"1","key":"3720_CR167","doi-asserted-by":"publisher","first-page":"011502","DOI":"10.1063\/5.0244706","volume":"9","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Tang Y, Luo D, Qiu J, Chen L. Advances in nanotechnology for targeting cancer-associated fibroblasts: a review of multi-strategy drug delivery and preclinical insights. APL Bioeng. 2025;9(1):011502. https:\/\/doi.org\/10.1063\/5.0244706. From NLM.","journal-title":"APL Bioeng"},{"issue":"2","key":"3720_CR168","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae \u2014 The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020.","journal-title":"J Control Release"},{"key":"3720_CR169","doi-asserted-by":"publisher","unstructured":"Wu J. The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. J Pers Med. 2021;11(8). https:\/\/doi.org\/10.3390\/jpm11080771. From NLM.","DOI":"10.3390\/jpm11080771"},{"key":"3720_CR170","doi-asserted-by":"publisher","unstructured":"Aloss K, Hamar P. Recent Preclinical and Clinical Progress in Liposomal Doxorubicin. Pharmaceutics. 2023;15(3). https:\/\/doi.org\/10.3390\/pharmaceutics15030893. From NLM.","DOI":"10.3390\/pharmaceutics15030893"},{"issue":"1","key":"3720_CR171","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13048-020-00736-2","volume":"14","author":"Z Yuan","year":"2021","unstructured":"Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, et al. Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer. J Ovarian Res. 2021;14(1):12. https:\/\/doi.org\/10.1186\/s13048-020-00736-2. From NLM.","journal-title":"J Ovarian Res"},{"issue":"9","key":"3720_CR172","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1634\/theoncologist.2013-0126","volume":"18","author":"JM Gibson","year":"2013","unstructured":"Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck NM. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist. 2013;18(9):1022\u201331. https:\/\/doi.org\/10.1634\/theoncologist.2013-0126. From NLM.","journal-title":"Oncologist"},{"key":"3720_CR173","doi-asserted-by":"publisher","unstructured":"Haemmerich D, Ramajayam KK, Newton D. A. Review of the Delivery Kinetics of Thermosensitive Liposomes. Cancers (Basel). 2023;15(2). https:\/\/doi.org\/10.3390\/cancers15020398. From NLM.","DOI":"10.3390\/cancers15020398"},{"issue":"1","key":"3720_CR174","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1038\/s41598-018-25930-7","volume":"8","author":"C Risnayanti","year":"2018","unstructured":"Risnayanti C, Jang YS, Lee J, Ahn HJ. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Sci Rep. 2018;8(1):7498. https:\/\/doi.org\/10.1038\/s41598-018-25930-7. From NLM.","journal-title":"Sci Rep"},{"issue":"1","key":"3720_CR175","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13036-022-00298-5","volume":"16","author":"J Wang","year":"2022","unstructured":"Wang J, Li B, Qiu L, Qiao X, Yang H. Dendrimer-based drug delivery systems: history, challenges, and latest developments. J Biol Eng. 2022;16(1):18. https:\/\/doi.org\/10.1186\/s13036-022-00298-5.","journal-title":"J Biol Eng"},{"issue":"12","key":"3720_CR176","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1021\/bc800342d","volume":"19","author":"RS Navath","year":"2008","unstructured":"Navath RS, Kurtoglu YE, Wang B, Kannan S, Romero R, Kannan RM. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjug Chem. 2008;19(12):2446\u201355. https:\/\/doi.org\/10.1021\/bc800342d. From NLM.","journal-title":"Bioconjug Chem"},{"key":"3720_CR177","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.1039\/B507350B","volume":"46","author":"R Shukla","year":"2005","unstructured":"Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker JJR. Tumor angiogenic vasculature targeting with PAMAM dendrimer\u2013RGD conjugates. Chem Commun Camb. 2005;46:5739\u201341. https:\/\/doi.org\/10.1039\/B507350B.","journal-title":"Chem Commun Camb"},{"key":"3720_CR178","doi-asserted-by":"publisher","unstructured":"Alven S, Aderibigbe B. A. The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment. Pharmaceutics. 2020;12(12). https:\/\/doi.org\/10.3390\/pharmaceutics12121212. From NLM.","DOI":"10.3390\/pharmaceutics12121212"},{"key":"3720_CR179","doi-asserted-by":"publisher","unstructured":"Nisha, Sachan RSK, Singh A, Karnwal A, Shidiki A, Kumar G. Plant-mediated gold nanoparticles in cancer therapy: exploring anti-cancer mechanisms, drug delivery applications, and future prospects. Front Nanotechnol. 2024;6.\u00a0https:\/\/doi.org\/10.3389\/fnano.2024.1490980. Review.","DOI":"10.3389\/fnano.2024.1490980"},{"key":"3720_CR180","doi-asserted-by":"publisher","first-page":"101559","DOI":"10.1016\/j.rechem.2024.101559","volume":"8","author":"A Hossain","year":"2024","unstructured":"Hossain A, Rayhan MT, Mobarak MH, Rimon MIH, Hossain N, Islam S, et al. Advances and significances of gold nanoparticles in cancer treatment: a comprehensive review. Results Chem. 2024;8:101559. https:\/\/doi.org\/10.1016\/j.rechem.2024.101559.","journal-title":"Results Chem"},{"issue":"1010","key":"3720_CR181","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1259\/bjr\/59448833","volume":"85","author":"S Jain","year":"2012","unstructured":"Jain S, Hirst DG, O\u2019Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012;85(1010):101\u201313. https:\/\/doi.org\/10.1259\/bjr\/59448833. From NLM.","journal-title":"Br J Radiol"},{"key":"3720_CR182","doi-asserted-by":"publisher","unstructured":"Vines JB, Yoon J-H, Ryu N-E, Lim D-J, Park H. Gold Nanoparticles for Photothermal Cancer Therapy. Front Chem. 2019;7.\u00a0https:\/\/doi.org\/10.3389\/fchem.2019.00167. Review.","DOI":"10.3389\/fchem.2019.00167"},{"issue":"1","key":"3720_CR183","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1038\/s41598-023-30526-x","volume":"13","author":"X Liu","year":"2023","unstructured":"Liu X, Zhou W, Wang T, Miao S, Lan S, Wei Z, et al. Highly localized, efficient, and rapid photothermal therapy using gold nanobipyramids for liver cancer cells triggered by femtosecond laser. Sci Rep. 2023;13(1):3372. https:\/\/doi.org\/10.1038\/s41598-023-30526-x.","journal-title":"Sci Rep"},{"key":"3720_CR184","doi-asserted-by":"publisher","unstructured":"Mahajan AS, Stegh AH. Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to Bedside. Cancers (Basel). 2022;14(7). https:\/\/doi.org\/10.3390\/cancers14071615. From NLM.","DOI":"10.3390\/cancers14071615"},{"key":"3720_CR185","doi-asserted-by":"publisher","unstructured":"Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021;13(584). https:\/\/doi.org\/10.1126\/scitranslmed.abb3945. From NLM.","DOI":"10.1126\/scitranslmed.abb3945"},{"key":"3720_CR186","doi-asserted-by":"publisher","unstructured":"Zhong Y, Li H, Li P, Chen Y, Zhang M, Yuan Z, Zhang Y, Xu Z, Luo G, Fang Y, et al. Exosomes: A New Pathway for Cancer Drug Resistance. Front Oncol. 2021;11.\u00a0https:\/\/doi.org\/10.3389\/fonc.2021.743556. Mini Review.","DOI":"10.3389\/fonc.2021.743556"},{"issue":"8","key":"3720_CR187","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1002\/ctm2.257","volume":"10","author":"S Li","year":"2020","unstructured":"Li S, Yi M, Dong B, Jiao Y, Luo S, Wu K. The roles of exosomes in cancer drug resistance and its therapeutic application. Clin Transl Med. 2020;10(8):e257. https:\/\/doi.org\/10.1002\/ctm2.257. From NLM.","journal-title":"Clin Transl Med"},{"key":"3720_CR188","doi-asserted-by":"publisher","unstructured":"Pulliero A, Mastracci L, Tarantini L, Khalid Z, Bollati V, Izzotti A. Let-7a Downregulation Accompanied by KRAS Mutation Is Predictive of Lung Cancer Onset in Cigarette Smoke-Exposed Mice. Int J Mol Sci. 2023;24(14). https:\/\/doi.org\/10.3390\/ijms241411778. From NLM.","DOI":"10.3390\/ijms241411778"},{"key":"3720_CR189","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2147\/ijn.S29661","volume":"7","author":"SA Kooijmans","year":"2012","unstructured":"Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine. 2012;7:1525\u201341. https:\/\/doi.org\/10.2147\/ijn.S29661. From NLM.","journal-title":"Int J Nanomedicine"},{"issue":"11","key":"3720_CR190","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41419-020-03189-z","volume":"11","author":"X Dong","year":"2020","unstructured":"Dong X, Bai X, Ni J, Zhang H, Duan W, Graham P, et al. Exosomes and breast cancer drug resistance. Cell Death Dis. 2020;11(11):987. https:\/\/doi.org\/10.1038\/s41419-020-03189-z.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3720_CR191","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/biom15010071","volume":"15","author":"L Kang","year":"2025","unstructured":"Kang L, Yue L, Minmin S, Wei X, Shanshan W, Xinxin Y, et al. Epigenetic regulation of Stromal and Immune Cells and therapeutic targets in the Tumor Microenvironment. Biomolecules. 2025;15(1):71\u201371. https:\/\/doi.org\/10.3390\/biom15010071.","journal-title":"Biomolecules"},{"issue":"1","key":"3720_CR192","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41467-017-01078-2","volume":"8","author":"EA Saunderson","year":"2017","unstructured":"Saunderson EA, Stepper P, Gomm JJ, Hoa L, Morgan A, Allen MD, et al. Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors. Nat Commun. 2017;8(1):1450. https:\/\/doi.org\/10.1038\/s41467-017-01078-2.","journal-title":"Nat Commun"},{"key":"3720_CR193","doi-asserted-by":"publisher","unstructured":"Zhang R, Yao T, Fan M, Jiang X, Wang K, Cui M, Bing K, Xia X. Precision scalpels for the epigenome: next-gen editing tools in targeted therapies. Front Med. 2025;12.\u00a0https:\/\/doi.org\/10.3389\/fmed.2025.1613722. Review.","DOI":"10.3389\/fmed.2025.1613722"},{"issue":"4","key":"3720_CR194","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/cncr.23601","volume":"113","author":"T Pal","year":"2008","unstructured":"Pal T, Permuth-Wey J, Sellers TA. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer. 2008;113(4):733\u201342. https:\/\/doi.org\/10.1002\/cncr.23601. From NLM.","journal-title":"Cancer"},{"issue":"6","key":"3720_CR195","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 In Vivo gene editing for Transthyretin Amyloidosis. N Engl J Med. 2021;385(6):493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454.","journal-title":"N Engl J Med"},{"issue":"2","key":"3720_CR196","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.apsb.2023.09.016","volume":"14","author":"Y Pan","year":"2024","unstructured":"Pan Y, Luan X, Zeng F, Wang X, Qin S, Lu Q, et al. Logic-gated tumor-microenvironment nanoamplifier enables targeted delivery of CRISPR\/Cas9 for multimodal cancer therapy. Acta Pharm Sin B. 2024;14(2):795\u2013807. https:\/\/doi.org\/10.1016\/j.apsb.2023.09.016.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"3720_CR197","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/s-0040-1721451","volume":"7","author":"Q Liu","year":"2020","unstructured":"Liu Q. World-First Phase I clinical trial for CRISPR-Cas9 PD-1-edited T-Cells in advanced Nonsmall Cell Lung Cancer. Glob Med Genet. 2020;7(3):73\u20134. https:\/\/doi.org\/10.1055\/s-0040-1721451. From NLM.","journal-title":"Glob Med Genet"},{"issue":"9","key":"3720_CR198","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188\u201398. https:\/\/doi.org\/10.1038\/s41423-021-00749-x.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"3720_CR199","doi-asserted-by":"publisher","first-page":"151463","DOI":"10.1016\/j.ejcb.2024.151463","volume":"103","author":"MM Rahman","year":"2024","unstructured":"Rahman MM, Tollefsbol TO. dCas9-HDAC8-EGFP fusion enables epigenetic editing of breast cancer cells by H3K9 deacetylation. Eur J Cell Biol. 2024;103(4):151463. https:\/\/doi.org\/10.1016\/j.ejcb.2024.151463. From NLM.","journal-title":"Eur J Cell Biol"},{"issue":"5","key":"3720_CR200","doi-asserted-by":"publisher","first-page":"e10764","DOI":"10.1371\/journal.pone.0010764","volume":"5","author":"M Susa","year":"2010","unstructured":"Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS ONE. 2010;5(5):e10764. https:\/\/doi.org\/10.1371\/journal.pone.0010764.","journal-title":"PLoS ONE"},{"issue":"9","key":"3720_CR201","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1038\/mtna.2013.45","volume":"2","author":"I Tekedereli","year":"2013","unstructured":"Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, et al. Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. Mol Ther Nucleic Acids. 2013;2(9):e121. https:\/\/doi.org\/10.1038\/mtna.2013.45. From NLM.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"3720_CR202","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.arcmed.2011.06.008","volume":"42","author":"ZX Wang","year":"2011","unstructured":"Wang ZX, Lu BB, Wang H, Cheng ZX, Yin YM. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res. 2011;42(4):281\u201390. https:\/\/doi.org\/10.1016\/j.arcmed.2011.06.008. From NLM.","journal-title":"Arch Med Res"},{"issue":"10","key":"3720_CR203","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1349-7006.2006.00287.x","volume":"97","author":"H Nozawa","year":"2006","unstructured":"Nozawa H, Tadakuma T, Ono T, Sato M, Hiroi S, Masumoto K, et al. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci. 2006;97(10):1115\u201324. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00287.x. From NLM.","journal-title":"Cancer Sci"},{"key":"3720_CR204","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1741-7015-10-28","volume":"10","author":"G Chen","year":"2012","unstructured":"Chen G, Kronenberger P, Teugels E, Umelo IA, De Gr\u00e8ve J. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28. https:\/\/doi.org\/10.1186\/1741-7015-10-28. From NLM.","journal-title":"BMC Med"},{"key":"3720_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9062004","author":"K Dhuri","year":"2020","unstructured":"Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, et al. Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9062004. From NLM.","journal-title":"J Clin Med"},{"issue":"5","key":"3720_CR206","first-page":"855","volume":"3","author":"BD Cheson","year":"2007","unstructured":"Cheson BD. Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag. 2007;3(5):855\u201370. From NLM.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"3720_CR207","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2217\/14796694.3.3.263","volume":"3","author":"AA Tarhini","year":"2007","unstructured":"Tarhini AA, Kirkwood JM. Oblimersen in the treatment of metastatic melanoma. Future Oncol. 2007;3(3):263\u201371. https:\/\/doi.org\/10.2217\/14796694.3.3.263.","journal-title":"Future Oncol"},{"issue":"29","key":"3720_CR208","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","volume":"24","author":"AY Bedikian","year":"2006","unstructured":"Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24(29):4738\u201345. https:\/\/doi.org\/10.1200\/JCO.2006.06.0483. Accessed 2025\/08\/14.","journal-title":"J Clin Oncol"},{"issue":"30","key":"3720_CR209","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.1200\/jco.2005.02.4364","volume":"23","author":"SM O'Brien","year":"2005","unstructured":"O\u2019Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of Oblimersen Sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced Chronic Lymphocytic Leukemia. J Clin Oncol. 2005;23(30):7697\u2013702. https:\/\/doi.org\/10.1200\/jco.2005.02.4364.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3720_CR210","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00280-012-1995-7","volume":"71","author":"PA Ott","year":"2013","unstructured":"Ott PA, Chang J, Madden K, Kannan R, Muren C, Escano C, et al. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol. 2013;71(1):183\u201391. https:\/\/doi.org\/10.1007\/s00280-012-1995-7.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9a","key":"3720_CR211","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1111\/j.1582-4934.2009.00876.x","volume":"13","author":"B Onnis","year":"2009","unstructured":"Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 2009;13(9a):2780\u20136. https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00876.x. From NLM.","journal-title":"J Cell Mol Med"},{"key":"3720_CR212","doi-asserted-by":"publisher","unstructured":"Vishnoi K, Viswakarma N, Rana A, Rana B. Transcription Factors in Cancer Development and Therapy. Cancers (Basel). 2020;12(8). https:\/\/doi.org\/10.3390\/cancers12082296. From NLM.","DOI":"10.3390\/cancers12082296"},{"issue":"1","key":"3720_CR213","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1124\/jpet.122.001234","volume":"384","author":"GM Traber","year":"2023","unstructured":"Traber GM, Yu AM. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. J Pharmacol Exp Ther. 2023;384(1):133\u201354. https:\/\/doi.org\/10.1124\/jpet.122.001234. From NLM.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"3720_CR214","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"J Tabernero","year":"2013","unstructured":"Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406\u201317.","journal-title":"Cancer Discov"},{"issue":"5","key":"3720_CR215","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265\u201380. https:\/\/doi.org\/10.1038\/s41576-021-00439-4.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"3720_CR216","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.3390\/ijms26083456","volume":"26","author":"O Ebenezer","year":"2025","unstructured":"Ebenezer O, Oyebamiji AK, Olanlokun JO, Tuszynski JA, Wong GK-S. Recent Update on siRNA Therapeutics. Int J Mol Sci. 2025;26(8):3456.","journal-title":"Int J Mol Sci"},{"key":"3720_CR217","doi-asserted-by":"publisher","unstructured":"Moaveni AK, Amiri M, Shademan B, Farhadi A, Behroozi J, Nourazarian A. Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update. Front Mol Biosci. 2024;11.\u00a0https:\/\/doi.org\/10.3389\/fmolb.2024.1382190. Review.","DOI":"10.3389\/fmolb.2024.1382190"},{"key":"3720_CR218","doi-asserted-by":"publisher","first-page":"4502846","DOI":"10.1155\/2016\/4502846","volume":"2016","author":"A Arcucci","year":"2016","unstructured":"Arcucci A, Ruocco MR, Granato G, Sacco AM, Montagnani S. Cancer: an oxidative crosstalk between solid tumor cells and cancer associated fibroblasts. Biomed Res Int. 2016;2016:4502846. https:\/\/doi.org\/10.1155\/2016\/4502846. From NLM Medline.","journal-title":"Biomed Res Int"},{"issue":"6","key":"3720_CR219","doi-asserted-by":"publisher","first-page":"1900213","DOI":"10.1002\/adtp.201900213","volume":"3","author":"L Ke","year":"2020","unstructured":"Ke L, Cai P, Wu Y-L, Chen X. Polymeric nonviral gene delivery systems for cancer immunotherapy. Adv Ther. 2020;3(6):1900213. https:\/\/doi.org\/10.1002\/adtp.201900213. Accessed 2023\/06\/28.","journal-title":"Adv Ther"},{"issue":"2","key":"3720_CR220","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10555-010-9224-5","volume":"29","author":"EC Finger","year":"2010","unstructured":"Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010;29(2):285\u201393. https:\/\/doi.org\/10.1007\/s10555-010-9224-5. From NLM Medline.","journal-title":"Cancer Metastasis Rev"},{"key":"3720_CR221","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","volume":"190","author":"JW Nichols","year":"2014","unstructured":"Nichols JW, Bae YHEPR. Evidence and fallacy. J Control Release. 2014;190:451\u201364. https:\/\/doi.org\/10.1016\/j.jconrel.2014.03.057. From NLM Medline.","journal-title":"J Control Release"},{"issue":"15_suppl","key":"3720_CR222","doi-asserted-by":"publisher","first-page":"TPS4672","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4672","volume":"38","author":"AM Varghese","year":"2020","unstructured":"Varghese AM, Ang C, Dimaio CJ, Javle MM, Gutierrez M, Yarom N, et al. A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT). J Clin Oncol. 2020;38(15_suppl):TPS4672\u2013TPS4672. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS4672. Accessed 2025\/08\/14.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3720_CR223","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/2159-8290.Cd-Nb2022-0071","volume":"13","author":"E Dolgin","year":"2023","unstructured":"Dolgin E. Personalized TCR T Cells Enabled by CRISPR. Cancer Discov. 2023;13(1):6\u20137. https:\/\/doi.org\/10.1158\/2159-8290.Cd-Nb2022-0071. Accessed 8\/14\/2025.","journal-title":"Cancer Discov"},{"key":"3720_CR224","doi-asserted-by":"publisher","unstructured":"Youssef E, Fletcher B, Palmer D. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Front Med. 2025;11.\u00a0https:\/\/doi.org\/10.3389\/fmed.2024.1527600. Review.","DOI":"10.3389\/fmed.2024.1527600"},{"issue":"7926","key":"3720_CR225","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609(7926):369\u201374. https:\/\/doi.org\/10.1038\/s41586-022-05140-y.","journal-title":"Nature"},{"issue":"9","key":"3720_CR226","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/ijc.31199","volume":"142","author":"SJ Gallagher","year":"2018","unstructured":"Gallagher SJ, Gunatilake D, Beaumont KA, Sharp DM, Tiffen JC, Heinemann A, et al. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Int J Cancer. 2018;142(9):1926\u201337. https:\/\/doi.org\/10.1002\/ijc.31199.","journal-title":"Int J Cancer"},{"issue":"1","key":"3720_CR227","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17568919.2024.2437975","volume":"17","author":"WB Liu","year":"2025","unstructured":"Liu WB, Song J, Zhang SY. A short overview of dual targeting HDAC inhibitors. Future Med Chem. 2025;17(1):5\u20137. https:\/\/doi.org\/10.1080\/17568919.2024.2437975. From NLM.","journal-title":"Future Med Chem"},{"issue":"7","key":"3720_CR228","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","volume":"1","author":"RA Juergens","year":"2011","unstructured":"Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non\u2013small cell lung cancer. Cancer Discov. 2011;1(7):598\u2013607. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0214. Accessed 8\/23\/2025.","journal-title":"Cancer Discov"},{"issue":"7","key":"3720_CR229","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1158\/0008-5472.CAN-18-2052","volume":"79","author":"K Fukuda","year":"2019","unstructured":"Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, et al. Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Cancer Res. 2019;79(7):1658\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2052. Accessed 8\/23\/2025. From NLM Medline.","journal-title":"Cancer Res"},{"key":"3720_CR230","doi-asserted-by":"publisher","first-page":"117658","DOI":"10.1016\/j.ejmech.2025.117658","volume":"292","author":"B Hou","year":"2025","unstructured":"Hou B, Jia G, Li Z, Jiang Y, Chen Y, Li X. Discovery of hydrazide-based PI3K\/HDAC dual inhibitors with enhanced pro-apoptotic activity in lymphoma cells. Eur J Med Chem. 2025;292:117658. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117658.","journal-title":"Eur J Med Chem"},{"key":"3720_CR231","doi-asserted-by":"publisher","unstructured":"Guo J, Jiang X, Lian J, Li H, Zhang F, Xie J, Deng J, Hou X, Du Z, Hao E. Evaluation of the effect of GSK-3\u03b2 on liver cancer based on the PI3K\/AKT pathway. Front Cell Dev Biol. 2024;12.\u00a0https:\/\/doi.org\/10.3389\/fcell.2024.1431423. Review.","DOI":"10.3389\/fcell.2024.1431423"},{"issue":"9","key":"3720_CR232","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797. https:\/\/doi.org\/10.1038\/s41419-020-02998-6.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3720_CR233","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41420-025-02470-4","volume":"11","author":"P Gou","year":"2025","unstructured":"Gou P, Fang C, Xu M, Zhang D, Wu X, Zhang L, et al. The dual HDAC\/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven Group 3 medulloblastoma. Cell Death Discov. 2025;11(1):172. https:\/\/doi.org\/10.1038\/s41420-025-02470-4.","journal-title":"Cell Death Discov"},{"key":"3720_CR234","doi-asserted-by":"publisher","unstructured":"Shukla YK, Vandana, Mandal V, Asati V, Keservani RK, Bharti SK. An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 - present): part 2 - patent published. Expert Opin Ther Pat. 2025;35(8):875\u2013900. https:\/\/doi.org\/10.1080\/13543776.2025.2516785. From NLM.","DOI":"10.1080\/13543776.2025.2516785"},{"issue":"11","key":"3720_CR235","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967\u201377. https:\/\/doi.org\/10.1038\/nmat3765. From NLM Medline.","journal-title":"Nat Mater"},{"issue":"14","key":"3720_CR236","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1021\/acsami.9b23084","volume":"12","author":"K Tu","year":"2020","unstructured":"Tu K, Deng H, Kong L, Wang Y, Yang T, Hu Q, et al. Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR\/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics-induced immunogenic cell death. ACS Appl Mater Interfaces. 2020;12(14):16018\u201330.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3720_CR237","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.biomaterials.2015.09.018","volume":"73","author":"Q Chen","year":"2015","unstructured":"Chen Q, Ke H, Dai Z, Liu Z. Nanoscale theranostics for physical stimulus-responsive cancer therapies. Biomaterials. 2015;73:214\u201330. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.09.018. From NLM Medline.","journal-title":"Biomaterials"},{"issue":"1","key":"3720_CR238","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13148-021-01154-x","volume":"13","author":"C Hu","year":"2021","unstructured":"Hu C, Liu X, Zeng Y, Liu J, Wu F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics. 2021;13(1):166. https:\/\/doi.org\/10.1186\/s13148-021-01154-x. From NLM.","journal-title":"Clin Epigenetics"},{"issue":"8","key":"3720_CR239","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2217\/epi-2016-0035","volume":"8","author":"G Reid","year":"2016","unstructured":"Reid G, Kao SC, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8(8):1079\u201385. https:\/\/doi.org\/10.2217\/epi-2016-0035. From NLM.","journal-title":"Epigenomics"},{"key":"3720_CR240","doi-asserted-by":"publisher","unstructured":"Pathak R, Halagali P, Tippavajhala VK, Dodakallanavar J, Ramachandra HD, Sharma H. Recent Advances in Targeted Nanocomposite-Based Therapeutics for Cancer Therapy. Curr Drug Res Rev. 2025. https:\/\/doi.org\/10.2174\/0125899775367848250226063700. From NLM.","DOI":"10.2174\/0125899775367848250226063700"},{"key":"3720_CR241","unstructured":"(FDA), U. S. F. a. D. A. Withdrawn | Cancer Accelerated Approvals. 12\/02\/2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-cancer-accelerated-approvals. Accessed 2025 August 16th."},{"issue":"9","key":"3720_CR242","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1016\/S1470-2045(23)00357-1","volume":"24","author":"A Cramer","year":"2023","unstructured":"Cramer A, S\u00f8rup FKH, Christensen HR, Petersen TS, Karstoft K. Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU? Lancet Oncol. 2023;24(9):e385\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(23)00357-1.","journal-title":"Lancet Oncol"},{"key":"3720_CR243","unstructured":"(FDA), U. S. F. a. D. A. Oncology (Cancer)\/Hematologic Malignancies Approval Notifications. 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancerhematologic-malignancies-approval-notifications. Accessed 2025 August 16."},{"issue":"8","key":"3720_CR244","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.1021\/acsnano.0c04707","volume":"14","author":"T Wei","year":"2020","unstructured":"Wei T, Cheng Q, Farbiak L, Anderson DG, Langer R, Siegwart DJ. Delivery of tissue-targeted scalpels: opportunities and challenges for in vivo CRISPR\/Cas-based genome editing. ACS Nano. 2020;14(8):9243\u201362. https:\/\/doi.org\/10.1021\/acsnano.0c04707.","journal-title":"ACS Nano"},{"key":"3720_CR245","doi-asserted-by":"publisher","unstructured":"VanDer Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Onco Targets Ther 2016;9:6065\u201374. https:\/\/doi.org\/10.2147\/OTT.S97644.","DOI":"10.2147\/OTT.S97644"},{"issue":"6","key":"3720_CR246","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/annonc\/mdw140","volume":"27","author":"K Dhingra","year":"2016","unstructured":"Dhingra K. Rociletinib: has the TIGER lost a few of its stripes? Ann Oncol. 2016;27(6):1161\u20134. https:\/\/doi.org\/10.1093\/annonc\/mdw140. Accessed 2025\/08\/15.","journal-title":"Ann Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03720-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03720-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03720-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:22:08Z","timestamp":1782915728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03720-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":246,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03720-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval is not applicable to this article, as it does not involve studies in human or animal subjects. Informed consent is therefore not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}